65.4 F
New York
Saturday, September 26, 2020
Home Healthcare

Healthcare

Healthcare company and market news.

Gilead Sciences, the drugmaker for remdesivir, the promising new coronavirus treatment, has announced that it will begin charging for the drug in July. The pharmaceutical company had been donating some of the medication for government distribution since May when it received emergency authorization use.
On Friday, the Food and Drug Administration gave emergency approval for the emergency treatment of the COVID-19 coronavirus with the use of remdesivir. The drug has been trialed as an experimental treatment in patients with the virus. The federal trial of the antiviral medication showed that remdesivir,...
As good news from Gilead Sciences about a possible coronavirus treatment hit the airways, stocks may end their best month in many decades. The S&P 500, in particular, is on track for its best performance since 1974. This, in spite, of sharp declines in economic activity within...
Shares of Gilead Sciences were up by more than 16 percent after-hours on Thursday once news of a promising drug trial broke. The drug, Remdesivir, is showing positive results in treating the novel coronavirus known as COVID-19. The drug trial is in phase 3...
Thirty volunteers from the nation’s largest tech companies built a coronavirus tracking site in six days. The volunteers from Apple, Amazon, Alphabet Google and others worked six straight nights to make it happen.  The team of volunteers worked closely with epidemiologists, including John Brownstein,...
Just as the coronavirus makes its way around the world, the U.S. reported its first death from the virus. A man in his 50s from Seattle, Washington who had chronic health issues was the first casualty of the disease. Meanwhile, a cluster outbreak was also reported in...
As concerns mount about the coronavirus, a dozen or so biotech companies have ramped up their efforts to fight the disease. And, investors are taking note. Vir Biotechnology stock soared 111 percent over the past month. Novavax also surged 91 percent. Investors are betting that biotech will...
In what will be an all-stock transaction, CoImmune Inc. and Formula Pharmaceutical have agreed to merge their companies. The pharma-enterprises will bring together two oncologic biotech platforms based on immune system therapies. In particular, the combined company will focus on a Phase 1 trial...
The U.S. Food and Drug Administration (FDA) has announced the approval of Ubrelvy, to Allergan USA, Inc., to treat migraine headaches. Ubrelvy, or its generic name ubrogepant, is part of a class of drugs that are oral calcitonin gene-related peptide receptor antagonists. The FDA says ubrogepant is...
The Canadian pharmaceutical biotech company, Aurinia, saw shares skyrocket on Thursday. Shares nearly doubled in a 24-hour period following good news about its lupus drug, voclosporin.  Lupus is a chronic autoimmune disease where a person’s own immune system becomes overactive. The result is that...